For instance, when paclitaxel was used to treat ovarian cancer cells derived from recurrent patient tumors, it triggered activation of the JAK2/STAT3 signaling pathway and led to elevated expression of CSC-associated genes and proteins in the cells that remained viable [106]. This evidence concerns the gene JAK2 and ovarian cancer.